A single-center observational study assessing the predictive factors associated with the prognosis of acromegaly
Authors:
- 1 December 2020
- journal article
- research article
- Published by Elsevier in Growth Hormone & IGF Research
- Vol. 55, 101342
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Factors Associated with Biochemical Remission after Microscopic Transsphenoidal Surgery for AcromegalyJournal of Neurological Surgery Part B: Skull Base, 2013
- Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysisPituitary, 2011
- Therapy of aggressive pituitary tumorsExpert Opinion on Pharmacotherapy, 2011
- Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extensionPituitary, 2009
- AcromegalyNew England Journal of Medicine, 2006
- Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin statusClinical Endocrinology, 2004
- Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist PegvisomantNew England Journal of Medicine, 2000
- Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experienceClinical Endocrinology, 1999
- The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenomaClinical Endocrinology, 1998
- Factors predicting pituitary adenoma invasiveness in acromegalic patientsNeurosurgical Review, 1997